A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
Conditions
Primary Immune Thrombocytopenia (ITP)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Peking University People's Hospital, Beijing, Beijing Municipality, China
North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Xi'an Central Hospital, Xi’an, Shanxi, China
Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
Study leads
Lei Zhang, M.D.
Principal Investigator
Hospital of Hematology, Chinese Academy of Medical Sciences
Yi Fang, Ph.D
Principal Investigator
Peking University People's Hospital